CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
LNA-i-miR-221biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04811898
NCT04811898Phase 1Completed
CompareCT.gov

A Dose Escalation Phase I Study of LNA-i-miR-221 for the Treatment of Refractory Multiple Myeloma and Advanced Solid Tumors

Azienda Ospedaliera Universitaria Mater Domini, Catanzaro·interventional·Posted Mar 23, 2021·Updated Feb 1, 2022

In Brief

A Phase 1 clinical trial evaluating LNA-i-miR-221 for Multiple Myeloma, Refractory and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The LNA-i-miR-221 Phase I trial has been designed as a monocentric open label dose escalation study which received written approval by the Competent Authority and independent Ethics Committee (IEC). LNA-i-miR-221 will be investigated for safety and tolerability in patients, men and women age ≥18 yrs, affected by Refractory-MM and advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Refractory, Hepatocarcinoma, Advanced Solid Tumor
CountriesItaly
CollaboratorsAssociazione Italiana per la Ricerca sul Cancro

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMar 23, 2021
Enrollment StartJan 14, 2019
Primary CompletionDec 29, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.3 years ago

Interventions

LNA-i-miR-221biological

LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)